SANGAMO THERAPEUTICS, INC.
corporate_fare Company Profile
SANGAMO THERAPEUTICS, INC. (OTC:SGMO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for SGMO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-06-23, rated 9/10. Across its 15 most recent items scored 7 or higher, the top rating is 10/10, with 13 rated 8 or above. Recent SEC coverage for SGMO spans 8-K/A, 8-K, 10-Q, 4.
Recent high-impact activity:
- Sangamo Therapeutics Sells Key Assets for Up to $100M Amidst Chapter 11 Bankruptcy
- SANGAMO THERAPEUTICS Files for Chapter 11 Bankruptcy, Initiates Asset Sales
- Sangamo Therapeutics Reports Q1 Loss, Reiterates Going Concern, and Confirms Nasdaq Delisting
- Sangamo Therapeutics Reports $31M Q1 Net Loss, $1.4M Revenue; Cash Runway into Q3 2026 Amid Nasdaq Delisting
- Sangamo Therapeutics Receives Nasdaq Delisting Notice; Trading Suspension Imminent
feed SGMO - Latest Insights
SGMO
Jun 23, 2026, 4:42 PM EDT
SGMO
Jun 23, 2026, 8:45 AM EDT
SGMO
May 14, 2026, 4:03 PM EDT
SGMO
May 14, 2026, 4:03 PM EDT
SGMO
Apr 29, 2026, 8:37 AM EDT
SGMO
Apr 23, 2026, 4:05 PM EDT
SGMO
Mar 30, 2026, 5:31 PM EDT
SGMO
Mar 30, 2026, 5:29 PM EDT
SGMO
Mar 30, 2026, 4:10 PM EDT
SGMO
Mar 09, 2026, 8:05 AM EDT
SGMO
Feb 04, 2026, 8:35 AM EST
SGMO
Feb 04, 2026, 8:31 AM EST
SGMO
Feb 03, 2026, 4:07 PM EST
SGMO
Feb 03, 2026, 9:07 AM EST
SGMO
Feb 03, 2026, 8:55 AM EST